Literature DB >> 28644772

Risk Stratification for Second Primary Lung Cancer.

Summer S Han1, Gabriel A Rivera1, Martin C Tammemägi1, Sylvia K Plevritis1, Scarlett L Gomez1, Iona Cheng1, Heather A Wakelee1.   

Abstract

Purpose This study estimated the 10-year risk of developing second primary lung cancer (SPLC) among survivors of initial primary lung cancer (IPLC) and evaluated the clinical utility of the risk prediction model for selecting eligibility criteria for screening. Methods SEER data were used to identify a population-based cohort of 20,032 participants diagnosed with IPLC between 1988 and 2003 and who survived ≥ 5 years after the initial diagnosis. We used a proportional subdistribution hazards model to estimate the 10-year risk of developing SPLC among survivors of lung cancer LC in the presence of competing risks. Considered predictors included age, sex, race, treatment, histology, stage, and extent of disease. We examined the risk-stratification ability of the prediction model and performed decision curve analysis to evaluate the clinical utility of the model by calculating its net benefit in varied risk thresholds for screening. Results Although the median 10-year risk of SPLC among survivors of LC was 8.36%, the estimated risk varied substantially (range, 0.56% to 14.3%) when stratified by age, histology, and extent of IPLC in the final prediction model. The stratification by deciles of estimated risk showed that the observed incidence of SPLC was significantly higher in the tenth-decile group (12.5%) versus the first-decile group (2.9%; P < 10-10). The decision curve analysis yielded a range of risk thresholds (1% to 11.5%) at which the clinical net benefit of the risk model was larger than those in hypothetical all-screening or no-screening scenarios. Conclusion The risk stratification approach in SPLC can be potentially useful for identifying survivors of LC to be screened by computed tomography. More comprehensive environmental and genetic data may help enhance the predictability and stratification ability of the risk model for SPLC.

Entities:  

Mesh:

Year:  2017        PMID: 28644772      PMCID: PMC5946715          DOI: 10.1200/JCO.2017.72.4203

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Model selection in competing risks regression.

Authors:  Deborah Kuk; Ravi Varadhan
Journal:  Stat Med       Date:  2013-02-24       Impact factor: 2.373

2.  Stage I lung cancer survivorship: risk of second malignancies and need for individualized care plan.

Authors:  Rakesh Surapaneni; Priya Singh; Kumar Rajagopalan; Alexandre Hageboutros
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

Review 3.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

6.  Targeting of low-dose CT screening according to the risk of lung-cancer death.

Authors:  Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

7.  Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study.

Authors:  Sang Min Park; Min Kyung Lim; Kyu Won Jung; Soon Ae Shin; Keun-Young Yoo; Young Ho Yun; Bong Yul Huh
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

Review 8.  Developing and evaluating polygenic risk prediction models for stratified disease prevention.

Authors:  Nilanjan Chatterjee; Jianxin Shi; Montserrat García-Closas
Journal:  Nat Rev Genet       Date:  2016-05-03       Impact factor: 53.242

9.  Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.

Authors:  Nancy R Cook; Paul M Ridker
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

10.  The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.

Authors:  David Rice; Hyung-Woo Kim; Anita Sabichi; Scott Lippman; J Jack Lee; Brendell Williams; Ara Vaporciyan; W Roy Smythe; Stephen Swisher; Garrett Walsh; Joe B Putnam; Waun Ki Hong; Jack Roth
Journal:  Ann Thorac Surg       Date:  2003-10       Impact factor: 4.330

View more
  33 in total

1.  Long-term CT surveillance after primary lung cancer treatment captures events in all risk groups.

Authors:  John Kang; Amit K Chowdhry; Michael T Milano
Journal:  Transl Lung Cancer Res       Date:  2018-02

2.  Can population data guide surveillance strategies for second primary lung cancers?

Authors:  Andrew J Arifin; Mark T Corkum; Alexander V Louie
Journal:  Transl Lung Cancer Res       Date:  2018-02

3.  The risk of second primary lung cancer: an unsolved dilemma.

Authors:  Antoinette J Wozniak; Ann G Schwartz
Journal:  Transl Lung Cancer Res       Date:  2018-02

4.  Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy.

Authors:  Dan Li; Chenhan Zhong; Xiujun Tang; Linzhen Yu; Kefeng Ding; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-19       Impact factor: 4.553

5.  Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study.

Authors:  Lishan Song; Chaojie Xu; Tong Zhang; Shengyang Chen; Zhigang Shi; Shuiquan Hu; Bingbing Cheng; Hao Tong; Guangkun Wei; Xiaoyong Li
Journal:  Front Surg       Date:  2022-08-30

6.  Caution Needed for Analyzing the Risks of Second Cancers.

Authors:  Summer S Han; Sylvia K Plevritis; Heather A Wakelee
Journal:  J Thorac Oncol       Date:  2018-09       Impact factor: 15.609

7.  Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database.

Authors:  Huaqiang Zhou; Jiayi Shen; Yaxiong Zhang; Yan Huang; Wenfeng Fang; Yunpeng Yang; Shaodong Hong; Jiaqing Liu; Wei Xian; Zhonghan Zhang; Yuxiang Ma; Ting Zhou; Hongyun Zhao; Li Zhang
Journal:  Ann Transl Med       Date:  2019-09

8.  Metabolomic profiling for second primary lung cancer: A pilot case-control study.

Authors:  Jacqueline V Aredo; Natasha Purington; Li Su; Sophia J Luo; Nancy Diao; David C Christiani; Heather A Wakelee; Summer S Han
Journal:  Lung Cancer       Date:  2021-03-11       Impact factor: 5.705

9.  Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Authors:  Jacqueline V Aredo; Sukhmani K Padda; Christian A Kunder; Summer S Han; Joel W Neal; Joseph B Shrager; Heather A Wakelee
Journal:  Lung Cancer       Date:  2019-05-15       Impact factor: 6.081

10.  Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.

Authors:  May Elbanna; Kevin Shiue; Donna Edwards; Alberto Cerra-Franco; Namita Agrawal; Jason Hinton; Todd Mereniuk; Christina Huang; Joshua L Ryan; Jessica Smith; Vasantha D Aaron; Heather Burney; Yong Zang; Jordan Holmes; Mark Langer; Richard Zellars; Tim Lautenschlaeger
Journal:  Clin Lung Cancer       Date:  2020-06-02       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.